« Back
Home /
Bilobetin

Bilobetin

Item no.	HY-N2118-20mg
Manufacturer	MedChem Express
CASRN	521-32-4
Amount	20 mg
Quantity options	10 mg 1 mg 20 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.39
Citations	[1]Kou XH, et al. Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet. Br J Pharmacol. 2012 Apr;165(8):2692-706.\|[2]Wang Q, et al. Bilobetin induces kidney injury by influencing cGMP-mediated AQP-2 trafficking and podocyte cell cycle arrest. Phytomedicine. 2019 Nov;64:153073. \|[3]Negm WA, et al. The Mechanistic Perspective of Bilobetin Protective Effects against Cisplatin-Induced Testicular Toxicity: Role of Nrf-2/Keap-1 Signaling, Inflammation, and Apoptosis. Biomedicines. 2022 May 13;10(5):1134\|[4]Han Ki Lee, et al. Bilobetin induces apoptosis in human hepatocellular carcinoma cells via ROS level elevation and inhibition of CYP2J2.Arabian Journal of Chemistry. Volume 16, Issue 9, September 2023, 105094.\|[5]Wang C, et al. Inhibition of Insulin-Like Growth Factor-1–Induced Sebum Production by Bilobetin in Cultured Human Sebocytes [J]. Annals of Dermatology, 2019, 31(3): 294.
Smiles	O=C1C=C(C2=CC=C(O)C=C2)OC3=C(C4=CC(C5=CC(C6=C(O)C=C(O)C=C6O5)=O)=CC=C4OC)C(O)=CC(O)=C13
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	521-32-4
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Akt; ERK; p38 MAPK; PKA; PPAR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	552.48
Product Description	Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity[1].
Manufacturer - Research Area	Metabolic Disease
Solubility	DMSO: 250 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad; Vitamin D Related/Nuclear Receptor
Isoform	PKA; PPARα
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-N2118-20mg-safety-datasheet.pdf